Drug policy for an aging population - The European Medicines Agency's geriatric medicines strategy

New England Journal of Medicine

Volumn 367, Issue 21, 2012, Pages 1972-1974

  Cerreta, Francesca ^a   Eichler, Hans Georg ^a   Rasi, Guido ^a,b  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG SURVEILLANCE PROGRAM; GERIATRIC CARE; GERIATRIC PATIENT; GERIATRICS; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; LAW; LIFE EXPECTANCY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SHORT SURVEY;

EID: 84869437442     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1209034     Document Type: Article

References (5)

1. European Medicines Agency. EMA geriatric medicines strategy (http://www.ema.europa.eu/docs/en-GB/document-library/Other/2011/02/WC500102291. pdf).
2. Cherubini A, Del Signore S, Ouslander J, Sem T, Michel P. Fighting against age discrimination in clinical trials. J Am Geriatr Soc 2010;58:1791-6.
3. European Medicines Agency. ICH harmonised tripartite guideline E7: studies in support of special populations: geriatrics questions and answers (http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 10/WC500005218.pdf).
4. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA 2011;305:50-8.
5. White paper: U.S. Food and Drug Administration (FDA) inventory of clinical trials protocols and clinical study data (www.fda.gov/downloads/Drugs/ DevelopmentApproval Process/ConductingClinicalTrials/UCM309552.pdf).